Invivyd reported preliminary Q4 2025 results with strong sequential and year-over-year revenue growth for PEMGARDA, driven by commercial execution. The company is advancing its pipeline with key clinical trial initiations and candidate selections, supported by recent capital raises.
Preliminary Q4 2025 PEMGARDA net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter.
positiveInitiated DECLARATION Phase 3 pivotal clinical trial for VYD2311 to prevent COVID, with top-line data expected mid-2026.
positiveVYD2311 granted Fast Track designation by the FDA in December 2025 for prevention of COVID in individuals with risk factors.
positiveNominated potential best-in-class RSV antibody candidate VBY329 for preclinical development.
positiveEnded 2025 with preliminary cash and cash equivalents of $226.7 million after raising over $200 million in 2H 2025.
positivePEMGARDA is an investigational mAb authorized under EUA, with limitations on data supporting its benefits and potential for reduced susceptibility to emerging variants.
attentionThe company's cash and cash equivalents are anticipated to be sufficient to support its operating plan, but future funding needs and market acceptance remain key considerations.
attentionThe company is still in the clinical development phase for key pipeline candidates, with significant regulatory and commercialization hurdles ahead.
attentionMargin metrics will be available once backend extracts data from insights_json
PEMGARDA revenue growth is attributed to commercial execution and the appeal of monoclonal antibody prophylaxis despite declining COVID vaccination trends.
Actively preparing for the potential commercial launch of VYD2311, an accessible vaccine-alternative for COVID prevention, which could be a step-change from PEMGARDA.
Well-positioned to support the DECLARATION pivotal trial and VYD2311 commercial launch with a strong balance sheet.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.